赛隆药业(002898) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥61,471,357.81, representing a 9.00% increase year-over-year[5] - Net profit attributable to shareholders decreased by 72.94% to ¥645,385.75, while the net profit after deducting non-recurring gains and losses was -¥2,437,223.98, a decrease of 1,269.27%[5] - Total operating revenue for Q3 2022 was CNY 192,836,032.37, an increase of 4.8% compared to CNY 185,425,358.96 in the same period last year[20] - Net profit for Q3 2022 was CNY 1,697,041.91, a decrease of 85.6% from CNY 11,800,954.52 in Q3 2021[21] - Basic and diluted earnings per share for Q3 2022 were CNY 0.0096, down from CNY 0.0671 in the same quarter last year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥865,697,964.81, down 1.94% from the end of the previous year[5] - Total current assets as of September 30, 2022, amount to CNY 269,064,623.01, a decrease from CNY 289,141,208.78 at the beginning of the year[17] - Total liabilities as of the end of Q3 2022 were CNY 300,339,882.34, a decrease from CNY 319,123,549.87 at the end of Q3 2021[21] - Non-current assets total CNY 596,633,341.80, slightly up from CNY 593,643,381.65[17] Cash Flow - The company’s cash flow from operating activities showed a net outflow of -¥6,959,283.72, a significant decrease of 276.88%[5] - Cash inflow from operating activities was CNY 182,336,417.97, compared to CNY 173,105,200.23 in Q3 2021[23] - Net cash flow from operating activities was -6,959,283.72, compared to 3,934,504.24 in the previous year, indicating a decline in operational performance[24] - Total cash outflow from operating activities amounted to 189,295,701.69, up from 169,170,695.99 year-over-year[24] Expenses - The gross profit margin decreased due to an increase in operating costs, which rose by 30.74% to ¥76,768,235.34[9] - Total operating costs for Q3 2022 were CNY 194,631,932.78, up 8.2% from CNY 179,954,786.92 in Q3 2021[20] - Research and development expenses for Q3 2022 amounted to CNY 17,743,407.29, an increase of 18.5% from CNY 14,988,989.35 in Q3 2021[21] - The company paid 34,865,231.00 in employee compensation, an increase from 30,710,939.77 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,357[13] - The largest shareholder, Cai Nanguai, holds 51.15% of shares, totaling 90,016,937 shares, with 67,512,703 shares pledged[13] - Total equity attributable to shareholders of the parent company was CNY 565,358,082.47, slightly up from CNY 563,661,040.56 in the previous year[21] Other Financial Metrics - The company received tax refunds amounting to ¥18,195,010.28, a substantial increase of 6,804.16% compared to the previous period[11] - Tax payments amounted to 12,102,323.46, slightly lower than 13,945,585.57 in the same period last year[24] - The company recorded a fair value gain of CNY 9,528,359.89 in Q3 2022, compared to CNY 3,750,252.83 in Q3 2021[21] - The company reported a significant increase in accounts receivable by 43.62% to ¥84,412,286.24, attributed to increased credit sales[8]